News: $SIEN Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter
SANTA BARBARA, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company (“Sientra" or the “Company”), today announced it has provided an initial response to the U.S. Food and Drug Administration (“FDA”) related ...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.